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Tenofovir disoproxil fumarate (TDF) is a first-line drug used
in patients with highly active retroviral disease; however,
it can cause renal failure associated with many tubular
anomalies that may be due to down regulation of a variety
of ion transporters. Because rosiglitazone, a peroxisome
proliferator-activated receptor-c agonist induces the
expression of many of these same transporters, we tested
if the nephrotoxicity can be ameliorated by its use. High
doses of TDF caused severe renal failure in rats accompanied
by a reduction in endothelial nitric-oxide synthase and
intense renal vasoconstriction; all of which were significantly
improved by rosiglitazone treatment. Low-dose TDF
did not alter glomerular filtration rate but produced
significant phosphaturia, proximal tubular acidosis,
polyuria and a reduced urinary concentrating ability. These
alterations were caused by specific downregulation of the
sodium-phosphorus cotransporter, sodium/hydrogen
exchanger 3 and aquaporin 2. A Fanconi’s-like syndrome
was ruled out as there was no proteinuria or glycosuria.
Rosiglitazone reversed TDF-induced tubular nephrotoxicity,
normalized urinary biochemical parameters and membrane
transporter protein expression. These studies suggest that
rosiglitazone treatment might be useful in patients
presenting with TFV-induced nephrotoxicity especially in
those with hypophosphatemia or reduced glomerular
filtration rate.
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Tenofovir disoproxil fumarate (TDF) is the first nucleotide
reverse transcriptase inhibitor approved for the treatment of
HIV.1 Presenting low protein binding, TDF is freely filtered
through the glomerulus without being degraded in the body.
Similar to cidofovir and adefovir, TDF is eliminated through
active tubular secretion via the human organic anion
transporter 1.2 High intracellular concentrations of TDF in
tubular cells can interfere with cell function.3
Currently, TDF is considered as a first-line drug for
patients who are highly active antiretroviral therapy
(HAART)-naı¨ve and is an option in many HAART combi-
nations.4 It has recently been shown that, in such anti-
retroviral-naı¨ve patients, the TDF–emtricitabine–efavirenz
combination is superior to the zidovudine–lamivudine–
efavirenz combination in terms of virological suppression
and CD4 response.5 In HIV-infected patients, treatment with
TDF has been associated with good virological suppression
and favorable clinical outcomes. However, TDF has serious
side effects, especially with long-term use. Among the
principal side effects associated with TDF use are hypo-
phosphatemia,6–8 renal failure,9,10 and tubular toxicity. The
tubular toxicity induced by TDF can manifest as renal
tubular acidosis,11 Fanconi syndrome,7,12,13 or nephrogenic
diabetes insipidus (NDI).7,13,14 Another significant side effect
is reduced bone mineral density.11,15 Through bone histology
in animals, it has been demonstrated that TDF treatment
causes osteomalacia,16 possibly by reducing serum phos-
phorus levels. Although the incidence of adverse effects is
low, the number of patients presenting with such side effects
is likely to grow in parallel with the increasing use of TDF.
The peroxisome proliferator-activated receptor-g (PPAR-g)
is a member of the nuclear receptor superfamily of ligand-
activated transcription factors. To regulate the transcription
of numerous target genes, ligand-activated PPAR-g binds to
a specific DNA site known as the peroxisome proliferator
response element.17,18 The PPAR-g is widely distributed
throughout the tissues, especially in adipose tissue. In renal
tissue, PPAR-g is expressed in the medullary collecting ducts,
proximal tubules, mesangial cells, and renal microvasculature.19
Song et al.20 demonstrated the effects that a PPAR-g
agonist has on transporters in the renal tubular epithelium.
The authors found that, in normal rats, the administration of
the PPAR-g agonist rosiglitazone (RSG) was associated with
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increased expression of the bumetanide-sensitive Na–K–2Cl
cotransporter (NKCC2), the sodium/hydrogen exchanger 3
(NHE3), and the sodium-phosphate cotransporter subtype
IIa (NaPi-IIa), as well as aquaporin 2 (AQP2). In addition,
RSG administration increased the expression of endothelial
nitric-oxide synthase (eNOS).
In this study, we investigated the mechanisms of
TDF-induced nephrotoxicity, focusing on its tubular effects.
We also tested the hypothesis that RSG protects against
TDF-induced renal impairment.
RESULTS
Three sets of experiments were performed. The first was
designated as the high-TDF (Hi-TDF) set. The Hi-TDF
experiments involved two groups: Hi-TDF (rats fed with a
diet containing 300 mg of TDF/kg of food for 30 days); and
Hi-TDFþRSG (rats fed with a diet containing 300 mg of
TDF/kg of food for the first 15 days and, for the subsequent
15 days, 300 mg of TDF plus 92 mg of RSG/kg of food). The
second set of experiments was designated as the low-TDF
(Lo-TDF) set. The Lo-TDF experiments involved two groups:
Lo-TDF (rats fed with a diet containing 50 mg of TDF/kg of
food for 30 days); and Lo-TDFþRSG (rats fed with a diet
containing 50 mg of TDF/kg of food for the first 15 days and,
for the subsequent 15 days, 50 mg of TDF plus 92 mg of
RSG/kg of food). For the Hi-TDF and Lo-TDF experiments,
we included a control group (rats fed with a normal diet for
30 days). The third set of experiments was designated as the
RSG-only set and involved a group designated as RSG (rats fed
with a diet containing 92 mg of RSG/kg of food for 15 days).
For the RSG-only experiments, we included an additional
control group (rats fed with a normal diet for 15 days). In all
three sets of experiments, each rat was provided with 25 g of
food per day, and all presented with similar ingestion (E23 g).
As can be seen in Tables 1 and 2, the TDF-induced
reduction in creatinine clearance was dose dependent. In the
Lo-TDF-treated rats, there were only minimal alterations in
renal blood flow (RBF), which were not accompanied by any
significant changes in creatinine clearance. Conversely,
creatinine clearance was significantly lower in the Hi-TDF
group rats than in the corresponding control rats.
High-dose TDF deteriorates renal function and induces
downregulation of eNOS protein abundance
The results of clearance studies and RBF measurements in the
Hi-TDF experiments are shown in Table 1. There were no
differences among the three groups in terms of body weight.
The rats in the Hi-TDF group presented with higher blood
pressure and significantly impaired renal function. These
alterations were accompanied by intense renal vasoconstric-
tion (reduced RBF and increased renal vascular resistance).
In addition, the Hi-TDF group rats presented with markedly
lower eNOS expression than the corresponding control rats
(Figure 1).
Table 1 | Renal function and hemodynamic measurements in normal (control) rats, in rats treated for 30 days with a high dose
of TDF (300 mg/kg of food; Hi-TDF group), and in rats treated for 30 days with the same high dose of TDF, to which RSG
(92 mg/kg of food) was added on day 15 and continued throughout (Hi-TDF+RSG group)
Group BW UO CrCl MAP RBF RVR
Control (n=4) 272±18 11.5±1.1 0.83±0.07 117±3.8 6.1±0.15 19.4±0.8
Hi-TDF (n=5) 259±15 13.9±2.1 0.19±0.01a 140±4.2b 2.3±0.20c,d 60.9±1.1a
Hi-TDF+RSG (n=5) 267±8 11.8±1.3 0.58±0.04e 125±3.5 4.3±0.35e 29.7±0.9e
BW, body weight (g); CrCl, creatinine clearance (ml/min/100 g); MAP, mean arterial pressure (mm Hg); RBF, renal blood flow (ml/min); RSG, rosiglitazone; RVR, renal vascular
resistance (mm Hg/ml/min); TDF, tenofovir disoproxil fumarate; UO, urine output (ml/day).
Data are expressed as mean±s.e.m.
aPo0.001 vs other groups.
bPo0.05 vs other groups.
cPo0.001 vs control.
dPo0.05 vs Hi-TDF+RSG.
ePo0.01 vs control by analysis of variance and Tukey’s multiple comparison test.
Table 2 | Renal function and hemodynamic measurements in normal (control) rats, in rats treated for 30 days with a low
dose of TDF (50 mg/kg of food; Lo-TDF group), and in rats treated for 30 days with the same low dose of TDF, to which RSG
(92 mg/kg of food) was added on day 15 and continued throughout (Lo-TDF+RSG group)
Group BW UO CrCl MAP RBF RVR
Control (n=4) 272±18 11.5±1.1 0.83±0.07 117±3.8 6.1±0.15 19.4±0.8
Lo-TDF (n=6) 274±12 23.4±1.6a 0.72±0.08 128±3.1 5.0±0.19b 25.6±1.3c
Lo-TDF+RSG (n=5) 262±6 8.4±1.1 0.74±0.01 117±2.8 5.9±0.35 19.8±0.9
BW, body weight (g); CrCl, creatinine clearance (ml/min/100 g); MAP, mean arterial pressure (mm Hg); RBF, renal blood flow (ml/min); RSG, rosiglitazone; RVR, renal vascular
resistance (mm Hg/ml/min); TDF, tenofovir disoproxil fumarate; UO, urine output (ml/day).
Data are expressed as mean±s.e.m.
aPo0.01 vs other groups.
bPo0.05 vs other groups.
cPo0.01 vs other groups by analysis of variance and Tukey’s multiple comparison test.
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RSG ameliorates renal function and restores eNOS protein
abundance in rats treated with high doses of TDF
Administration of RSG improved renal function, as evi-
denced by the fact that creatinine clearance was significantly
greater in the Hi-TDFþRSG group than in the Hi-TDF
group. There was no difference in creatinine clearance
between the rats in the RSG group and those in the
corresponding control group (0.58±0.03 vs 0.68±0.05 ml/
min/100 g body weight). Renal vasoconstriction was lower in
the Hi-TDFþRSG group than in the Hi-TDF group
(Table 1). In addition, RSG inhibited the TDF-induced
downregulation of eNOS expression (Figure 1).
Tubular dysfunction associated with the administration of
low doses of TDF
In terms of creatinine clearance, there was no significant
difference between the Lo-TDF group rats and the corre-
sponding control group rats (Table 2). In the Lo-TDF group
rats, urine output was significantly greater than that observed
in the control rats (Table 3). The Lo-TDF group rats also
presented with markedly lower urine osmolality than did
the control rats. Proximal tubular function was impaired in
Lo-TDF-treated rats, as evidenced by increased urinary
phosphorus excretion and a considerable reduction in serum
bicarbonate. Other markers of proximal tubular dysfunction,
such as glycosuria and proteinuria, were absent (data not
shown). No differences were observed in urinary sodium
excretion or urinary potassium excretion. In addition, we
observed no differences between the Lo-TDF-treated rats and
the corresponding control rats in terms of urinary calcium
excretion or urinary magnesium excretion. Administration of
RSG reversed the hyperphosphaturia presented by the rats in
the Lo-TDF group. In Lo-TDFþRSG-treated rats, urinary
phosphorus excretion returned to normal levels by the end of
the experiment (Table 3). The acidosis presented by rats in
the Lo-TDF group was not observed in the Lo-TDFþRSG
group. The Lo-TDF group rats presented with partial NDI, by
which time urine output and osmolality had normalized in
the Lo-TDFþRSG-treated rats (Table 3).
Interestingly, compared with the corresponding control
group rats, the RSG group rats presented with an increase in
body weight, as well as an increase in urinary osmolality.
However, there was no difference between the two groups in
terms of urine volume. Surprisingly, the RSG group rats also
presented significantly greater urinary excretions than those
in the corresponding control group, including urinary
excretion of sodium, potassium, and phosphorus (Table 4).
NaPi-IIa cotransporter protein abundance is decreased in
TDF-treated rats
Tubular reabsorption of phosphorus is largely performed in
the proximal tubules via NaPi-IIa. To investigate the cause
of hyperphosphaturia in TDF-treated rats, we examined
NaPi-IIa expression in the renal cortex. As shown in Figure 2a,
NaPi-IIa protein expression in TDF-treated rats was signi-
ficantly lower than that seen in control rats (67.7±1.4 vs
99.5±0.5%, Po0.01).
Treatment with TDF induces renal tubular acidosis through
downregulation of NHE3
Although rats treated with TDF presented with low serum
bicarbonate levels and low serum pH, urine pH also
remained low (Table 3), suggesting proximal tubular
dysfunction. To thoroughly investigate the cause of the
serum acidosis, we examined NHE3 protein expression. In
comparison with control rats, those treated with TDF
presented with lower NHE3 protein expression (100±1 vs
59±2.1%, Po0.01; Figure 2b), which is consistent with the
proximal type of renal tubular acidosis.
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Figure 1 | Semiquantitative immunoblotting of kidney
fractions. (a) Densitometric analysis of all samples from control,
high-dose TDF (Hi-TDF) and Hi-TDFþ rosiglitazone (Hi-TDFþ RSG)
rats. The Hi-TDF group rats presented with decreased endothelial
nitric oxide synthase (eNOS) expression. Levels of eNOS
expression were completely restored in response to RSG.
(b) Immunoblots that reacted with anti-eNOS. *Po0.001 vs
control and Hi-TDFþ RSG group.
Table 3 | Functional parameters in normal (control) rats, in
rats treated for 30 days with a low dose of TDF (50 mg/kg of
food; Lo-TDF group), and in rats treated for 30 days with the
same low dose of TDF, to which RSG (92 mg/kg of food) was
added on day 15 and continued throughout (Lo-TDF+RSG
group)
Control Lo-TDF Lo-TDF+RSG
Urine output (ml/day) 11.5±0.5 23.4±1.6a 8.4±1.1
UOsm (mOsm/kg H2O) 988±101 520±85
b,c 1360±138c
UPV (mmol/day) 316±33 648±41
a 351±36
UNaV (mEq./day) 1.30±0.22 1.45±0.14 1.46±0.15
UKV (mEq./day) 1.16±0.21 1.65±0.38 1.48±0.18
UMgV (mg/day) 0.96±0.26 0.92±0.28 1.04±0.13
UCaV (mg/day) 354±25 298±22 362±32
PH 7.42±0.01 7.31±0.02a 7.42±0.02
Serum bicarbonate (mEq./l) 24.6±1.2 18.3±0.8d 23.7±1.0
Serum anion gape 18.3±1.8 17.9±2.0 18.5±1.6
RSG, rosiglitazone; TDF, tenofovir disoproxil fumarate; UOsm, urinary osmolality;
UNaV, urinary sodium; UKV, urinary potassium; UPV, urinary phosphorus; UMgV,
urinary magnesium; UCaV, urinary calcium.
aPo0.001 vs control and Lo-TDF+RSG.
bPo0.001 vs Lo-TDF+RSG.
cPo0.05 vs control.
dPo0.05 vs control and Lo-TDF+RSG.
eAnion gap is calculated as sodium-chloride-bicarbonate.
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Abundance of a-ENaC in the renal cortex is unchanged
in TDF-treated rats
Figure 3 shows representative immunoblots of renal cortex
homogenates probed with the antibody against the a-subunit
of the epithelial sodium channel (a-EnaC). Abundance
of a-ENaC was unaffected by TDF treatment (Lo-TDF:
108.3%±1.7; control: 100%, P¼NS).
NKCC2 protein expression is increased in rats treated with
TDF: a compensatory mechanism
Protein expression of NHE3 was reduced in TDF-treated rats.
As no increase in urinary sodium excretion was observed in
the treated rats, we attempted to determine whether distal
segments of the nephron play a compensatory role by
reabsorbing the excess sodium delivered. It is well known that
apical NKCC2 is the major transporter for sodium reabsorp-
tion by the thick ascending limb. As indicated in Figure 4a,
NKCC2 protein expression was significantly higher in the
medullae of Lo-TDF group rats than in those of control rats
(136±2.2 vs 99±1.0%, Po0.001).
AQP2 abundance in the renal medulla is altered in response
to TDF treatment
As can be seen in Figure 4b, treatment with TDF reduced
AQP2 abundance significantly (67.5±2.5 vs 99±1, Po0.01).
This can partially explain the reduced urinary concentrating
ability.
Table 4 | Functional parameters in normal (control) rats and in rats treated for 15 days with RSG (92 mg/kg of food, RSG group)
BW (g) UOsm (mOsm/kg H2O) Urine output (ml/day) UNaV (mEq./day) UKV (mEq./day) UPV (lmol/day)
Control group 252±7 410±73 26±3.2 0.6±0.05 1.2±0.04 524±25
RSG group 293±6a 627±55b 22±3.1 1.48±0.15a 1.4±0.08b 848±35.4a
BW, body weight, RSG, rosiglitazone; UOsm, urinary osmolality; UNaV, urinary sodium; UKV, urinary potassium; UPV, urinary phosphorus.
aPo0.001 vs control.
bPo0.05 vs control.
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Figure 2 | Semiquantitative immunoblotting of membrane
fractions prepared from renal cortices. Densitometric analysis
of all samples from control, low-dose TDF (Lo-TDF),
Lo-TDFþ rosiglitazone (Lo-TDFþ RSG), and rosiglitazone (RSG) rats.
(a) The Lo-TDF group rats presented with decreased expression of
sodium-phosphate cotransporter subtype IIa (NaPi-IIa). Levels of
NaPi-IIa expression were completely restored in response to RSG.
Immunoblots reacted with anti-NaPi-IIa, revealing an 85-kDa band.
(b) The Lo-TDF group rats presented decreased expression of the
sodium/hydrogen exchanger 3 (NHE3). Levels of NHE3 expression
were completely restored in response to RSG. Immunoblots
reacted with anti-NHE3 revealing an 84-kDa band.
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Figure 3 | Semiquantitative immunoblotting of membrane
fractions prepared from renal cortices. Densitometric analysis
of all samples from control, low-dose TDF (Lo-TDF),
Lo-TDFþ rosiglitazone (Lo-TDFþ RSG), and rosiglitazone (RSG)
rats. The Lo-TDF group rats presented with normal expression
of a-ENaC. Levels of a-ENaC expression were increased in
response to RSG. Immunoblots reacted with anti-a-ENaC,
revealing an 86-kDa band.
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RSG reverses the TDF-induced downregulation of NaPi-IIa
In rats receiving low-dose TDF, RSG restored NaPi-IIa
expression (Figure 2a), explaining the normalization of
phosphaturia observed in the Lo-TDFþRSG group. There
was no significant difference between the RSG group rats
and the controls in terms of NaPi-IIa expression (RSG:
89.3±2.3%).
RSG ameliorates TDF-induced renal tubular acidosis by
restoring NHE3 abundance
In the Lo-TDFþRSG-treated rats, NHE3 protein expression
was higher than that seen in the Lo-TDF group rats
(93.3±4.4 vs 59±2.1, Po0.01; Figure 2b), and NHE3
protein abundance was comparable with that observed in
control rats (93.3±4.4 vs 100±1%, P¼NS). The RSG group
rats presented with no significant difference in serum pH or
NHE3 expression in comparison with the control group rats
(RSG: 108±7.3%).
a-ENaC protein expression is significantly increased in rats
treated with TDF and RSG
Figure 3 shows that a-ENaC expression was greater in the
Lo-TDFþRSG-treated rats than in the Lo-TDF-treated rats
(145±2.9 vs 108.3±1.7%, Po0.001). In addition, a-ENaC
expression was greater in the Lo-TDFþRSG-treated rats
than in control rats (145±2.9 vs 100%, Po0.001). In the
RSG group, a-ENaC expression was increased in comparison
with the control group (RSG: 155±2.9%, Po0.001). In
addition, there was a significant difference between the RSG
group and the Lo-TDFþRSG group in terms of a-ENaC
expression, which was greater in the RSG group (Po0.05).
NKCC2 protein expression is increased in rats treated with
TDF and RSG
Figure 4a shows that Lo-TDFþRSG rats presented with
levels of NKCC2 expression comparable with those seen in
Lo-TDF group rats (145±2.9 vs 136±2.2%, P¼NS).
Expression of NKCC2 was significantly higher in the
Lo-TDFþRSG and Lo-TDF group rats than in the control
rats and in the RSG rats (Po0.001). In the RSG group,
NKCC2 expression did not differ significantly from that
observed for the controls (RSG: 111±5.2%).
AQP2 protein expression is significantly increased in rats
treated with TDF and RSG
Figure 4b shows that Lo-TDFþRSG rats presented greater
AQP2 expression than that seen in the Lo-TDF group rats
(143.3±7.2 vs 67.5±2.5%, Po0.001). In addition, AQP2
abundance was greater in Lo-TDFþRSG rats than in control
rats (143.3±7.2 vs 99±1%, Po0.001). In the RSG group,
AQP2 expression increased in comparison with that observed
in the control group (RSG group: 165±5.4%, Po0.001). In
addition, there was a significant difference between the RSG
group and the Lo-TDFþRSG group in terms of AQP2
expression, which was higher in the RSG group (Po0.05).
DISCUSSION
Treatment with TDF induced a broad spectrum of nephro-
toxicity, including renal failure, proximal tubular injury
(hyperphosphaturia and renal tubular acidosis), and reduced
urinary concentrating ability. The dose-dependent deteriora-
tion in renal function was associated with renal vasoconstric-
tion and reduced abundance of eNOS. We also demonstrated
downregulation of membrane transporters (NaPi-IIa, NHE3,
and AQP2). Most importantly, RSG reversed all TDF-
induced renal alterations. It has been demonstrated that
changes in the expression of membrane protein transporters
can occur in many forms of acute kidney injury, including
those caused by ischemia or nephrotoxicity.21,22 However, it
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Figure 4 | Semiquantitative immunoblotting of membrane
fractions prepared from kidney medulla. Densitometric analysis
of all samples from control, low-dose TDF (Lo-TDF),
Lo-TDFþ rosiglitazone (Lo-TDFþ RSG), and rosiglitazone (RSG)
rats. (a) The Lo-TDF and Lo-TDFþ RSG rats presented increased
expression of the bumetanide-sensitive Na–K–2Cl cotransporter
(NKCC2) in relation to controls. Immunoblots reacted with anti-
NKCC2 revealing a band of 146–176 kDa (centered at 161 kDa).
(b) Levels of AQP2 expression were completely restored in
response to RSG, also increasing in relation to controls.
Immunoblots reacted with anti-AQP2 revealing 29-, 35-,
and 50-kDa AQP2 bands.
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remains unknown whether these alterations are specific to
injury caused by TDF administration or are simply
characteristic of how renal tubular cells react under stress
(for example, ischemia) Nevertheless, in this study, altera-
tions of this type occurred in rats treated with tenofovir.
Renal failure induced by TDF is dose dependent and is
associated with reduced production of NO
In experimental studies involving isolated human proximal
tubular cells, TDF presented with lower cytotoxicity than
other nucleoside reverse transcriptase inhibitors.23 However,
there are studies showing that patients using TDF-containing
HAART regimens present with renal dysfunction, whereas
control HIV patients do not.24 In other reports, the incidence
of renal failure associated with TDF-containing HAART
regimens is no different from that associated with other
HAART regimens.25,26
For treatment-naı¨ve patients, as well as for treatment-
experienced patients, TDF has rapidly become a favored
nucleoside component of antiretroviral regimens.
In this study, rats receiving high-dose TDF developed
severe renal failure accompanied by intense renal vaso-
constriction, neither of which was observed in those receiving
the low dose. It has been suggested that TDF causes direct
proximal tubular damage, leading to renal failure.27 We have
demonstrated herein that another mechanism contributes to
TDF-induced renal failure, namely diminished production of
NO. In previous studies conducted by our group in patients
and in animal models, we found that indinavir also decreases
NO production.28,29
RSG reverses TDF-induced downregulation of eNOS and
ameliorates renal function
Various studies have shown that PPAR-g agonists are
efficacious in slowing the progression of glomerulosclerosis
(diabetic and nondiabetic), ischemia–reperfusion injury, and
cisplatin nephrotoxicity.19,30–32 Polikandriotis et al.33 demon-
strated that RSG increased NO production via distinct PPAR-
dependent signaling pathways. Song et al.20 studied normal
rats receiving RSG and showed that eNOS expression in the
renal tissue was increased, blood pressure was lowered, and
creatinine clearance was reduced. In this study, we demon-
strated that 15 days of treatment with RSG did not alter
creatinine clearance. In addition, eNOS upregulation was
found to be associated with improved renal function in rats
receiving TDF. We speculate that, under conditions of renal
vasoconstriction, such as that resulting from the administra-
tion of TDF, RSG-induced vasodilatation has beneficial
effects.
Tubular proximal damage induced by TDF can be
selective to sodium transporters
In the Lo-TDF experiments, we found tubular alterations and
minor (not statistically significant) changes in creatinine
clearance. It has been demonstrated that renal tubular
dysfunction, with or without a decrease in glomerular
filtration rate, occurs in patients.34 It has been demonstrated
that TDF use provokes proximal tubular dysfunction,
including glycosuria, tubular proteinuria, hyperphospha-
turia, and renal tubular acidosis. Kinai and Hanbusa34
studied patients initiating a TDF-containing HAART regimen
and reported that 12 out of 17 presented with high levels of
urinary b-2 microglobulin accompanied by significant
decreases in tubular reabsorption of phosphate.
In our experimental model of TDF nephrotoxicity, the
effects on the proximal tubules appeared to be specific to
sodium transporters (NHE3 and NaPi-IIa), as no glycosuria
or increased proteinuria was observed. It is possible that, in
rats, prolonged exposure to TDF would cause generalized
proximal tubular dysfunction such as that described in
humans.
One of the most consistent findings in patients suffering
from TDF nephrotoxicity is hypophosphatemia.12 The rats in
the Lo-TDF group presented with hyperphosphaturia, which
is the most likely cause of the hypophosphatemia seen
in those same rats. It is of note that, despite presenting
with metabolic acidosis, these animals developed hypo-
phosphatemia.
In the Lo-TDF group rats, expression of the NaPi-IIa
cotransporter was downregulated. This transporter is located
in the proximal tubule and is responsible for nearly 80% of
phosphate reabsorption along the nephron. The mechanism
by which TDF downregulates NaPi-IIa expression remains
unexplained. However, the high TDF levels in the proximal
tubules might account for this tubular cellular dysfunction.
The nonanion-gap metabolic acidosis observed in the rats
studied is consistent with the proximal type of renal tubular
acidosis, as the pH of urine remained low. Located in the
proximal tubule, the NHE3 countertransporter is the
principal agent of final bicarbonate generation and reabsorp-
tion. We found that NHE3 was downregulated in renal cortex
tissue, implicating NHE3 reduction in TDF-induced meta-
bolic acidosis. The possibility that other transporters
(basolateral carbonic anhydrase II and IV or sodium-
bicarbonate cotransporter (NBC1)) are involved in TDF-
related metabolic acidosis cannot be ruled out.
Although TDF-treated rats presented with a marked
reduction in proximal sodium transporter abundance,
there was no difference between TDF-treated rats and the
corresponding control rats in terms of urinary sodium
excretion. As a consequence of the decreased protein
expression of sodium transporters (especially NHE3), fluid
delivery to the distal nephron might be increased. It is
possible that the marked increase in NKCC2 band density
presented by the TDF-treated rats represents a compensatory
response to the greater delivery of sodium chloride and water.
It has been shown that sodium transporter abundance is
upregulated in response to chronic diuretic treatment in
rats.35 This compensatory mechanism could explain the
absence of increased kaliuresis in this model of nephro-
toxicity, despite the fact that hypokalemia has been reported
in patients receiving TDF.36
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Tubular toxicity induced by TDF is not restricted to proximal
cells
Several cases of NDI have been described in patients
receiving TDF.7,13,14 In all cases, the patients also received
ritonavir or lopinavir, which have been implicated in altered
water–electrolyte balance. Multidrug resistance protein 1
is expressed in the basolateral membranes of cells in the
proximal tubules, in Henle’s loop and in the cortical
collecting duct. Inhibition of multidrug resistance protein 1
leads to reduced renal tubular responsiveness to vasopressin
and can, at least in part, be the cause of NDI. In addition, it is
known that ritonavir inhibits multidrug resistance protein 1.
Therefore, it has been hypothesized that the TDF–ritonavir
combination induces NDI in some patients.27 However, we
have demonstrated herein that TDF has the direct effect of
reducing the abundance of AQP2, thereby impairing urinary
concentrating ability and leading to a state of partial NDI.
In a previous study, Andrade et al.21 found that another
antiviral agent, acyclovir, induced hyperphosphaturia and
hypophosphatemia, which were accompanied by polyuria as
well as by increased urinary excretion of sodium, potassium,
and magnesium. Similar to tenofovir, acyclovir induced
downregulation of Na-Pi-IIa and AQP2 expression. However,
unlike tenofovir, acyclovir downregulated NKCC2 expression.
As acyclovir is the drug of choice for the treatment of
herpes virus simplex encephalitis and varicella-zoster infec-
tion in immunocompromised hosts, it is not unusual for the
combination of acyclovir and tenofovir to be used in HIV
patients, thereby increasing the risk of nephrotoxicity.
Treatment with RSG completely reverses TDF-induced
tubular toxicity
It is known that PPAR-g is expressed in renal tubular cells,
especially those in the collecting duct and also those in the
proximal tubule.19 Song et al.20 studied the effects of RSG on
the renal tubules of rats. The authors showed that treatment
with RSG significantly increased renal abundance of NHE3,
NaPi-IIa, NKCC2, and AQP2. These data provide the basis for
the theory that RSG reverses TDF-induced tubular toxicity.
In addition to its protective effect in TDF-induced renal
failure, RSG completely reverses the downregulation of NaPi-
IIa, NHE3 countertransporter, and AQP2, thereby reverting
hyperphosphaturia, metabolic acidosis, and NDI. It is possible
that the higher glomerular filtration rate in the Hi-TDFþRSG
group rats resulted from the extracellular volume expansion
caused by RSG. However, body weight, which is a measure of
extracellular volume expansion, was not significantly higher in
the Hi-TDFþRSG or Lo-TDFþRSG groups in comparison
with the TDF-only and control groups. However, a significant
weight gain was observed in the RSG-only group.
Glomerular filtration and active tubular secretion partially
eliminate TDF. In the latter case, organic anion transporters
carry TDF through the basolateral membrane, after which it
is secreted into the lumen. This second route of elimination
leads to a high TDF concentration in proximal tubular cells,
which can increase its toxicity.37
As RSG is extensively metabolized, the unadulterated
form of the drug is not excreted in urine. The major forms
of metabolism are N-demethylation and hydroxylation,
followed by conjugation with sulfate and glucuronic acid.
All of the circulating metabolites of RSG are considerably less
potent than the parent.38 It has been shown that, following
oral or intravenous administration of [14C] RSG maleate,
approximately 64 and 23% of the dose is eliminated in the
urine and in the feces, respectively.38 There are convincing
data in the literature demonstrating RSG-induced increases
in the protein expression of sodium transporters and of
AQP220,39,40 However, there are few data demonstrating
how such increases occur. It is not completely understood
how RSG affects the expression of all renal transporters, and
there are few data available on this topic. Guan et al.36
demonstrated that thiazolidinediones increase the mRNA
expression of Scnn1g, which encodes the gamma subunit
of ENaC, indicating that PPAR-g has a direct effect on that
gene.
An increased risk of myocardial infarction and death from
cardiovascular causes has been attributed to RSG use.41 In
addition, 10–15% of patients treated with thiazolidinediones
develop edema, which often requires the discontinuation of
therapy.42 In our study, body weight and urinary osmolality
were both higher in the RSG group than in the corresponding
control group. The RSG group also presented a significant
increase in the urinary excretion of sodium, potassium, and
phosphorus in comparison with the corresponding control
group. We hypothesize that the greater urinary excretion of
these ions is associated with extracellular volume expansion,
caused by an increase in a-ENaC and AQP2 protein
expression. Considering these recent findings, the clinical
use of RSG should be evaluated with caution; patients and
providers should bear in mind that treatment with RSG can
have serious adverse effects.
In conclusion, TDF caused renal failure in a dose-
dependent matter, leading to a great reduction in eNOS
expression and intense renal vasoconstriction. In addition,
we found that TDF-induced tubular toxicity involved
downregulation of NHE3, NaPi-Iia, and AQP2. We found
no proteinuria or glycosuria, although such disorders might
appear after prolonged use of TDF. Furthermore, the
upregulation of NKCC2 in rats treated with TDF appears
to be a compensatory mechanism triggered by greater
sodium delivery to the distal nephron segments. Moreover,
in this animal model, RSG reversed all mechanisms of
TDF-induced nephrotoxicity, re-establishing the expression
of eNOS, NHE3, NaPi-Iia, and AQP2, as well as normalizing
biochemical parameters. Further studies are needed to
determine whether these findings are specific and represen-
tative of the effects of TDF use in humans.
MATERIALS AND METHODS
Animals
For the purposes of this study, male Wistar rats, weighing 200–230 g,
were obtained from the University of Sa˜o Paulo School of Medicine
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animal facilities. The Hi-TDF experiments were designed on the basis
of a previous study in rats.43 However, the Hi-TDF dosage caused
severe impairment of renal function. We used this dosage to assess
creatinine clearance, RBF, renal vascular resistance, and whole-kidney
eNOS expression. The Lo-TDF experiments allowed us to assess
tubular function without provoking significant impairment of
creatinine clearance.
The Ethics Committee of the University of Sa˜o Paulo School of
Medicine approved the experimental protocol.
Metabolic cage studies and renal function studies
At 30 days, rats were moved to metabolic cages (one rat per cage),
maintained on a 12-h light/dark cycle and given free access to
drinking water. The rats were acclimated to the housing conditions
for 1 day before the experimental procedures, which began with
the collection of 24-h urine samples. Rats in the Hi-TDF groups
were anesthetized with intraperitoneal injections of sodium
pentobarbital (50 mg/kg body weight) and placed on a tempera-
ture-regulated surgical table. A tracheotomy was performed, and
a PE50 catheter was inserted into the left femoral artery to
record mean arterial pressure. An ultrasonic flow probe (T-106;
Transonic Systems Inc., Ithaca, NY, USA) was placed at the left
renal artery to monitor RBF. Final blood samples were obtained,
and the animals were then killed with a lethal dose of sodium
pentobarbital.
Analysis of blood and urine samples
The volume of each 24-h urine sample was measured gravime-
trically. Urine samples were centrifuged in aliquots to remove
suspended material, and the supernatants were analyzed. Urine
osmolality was measured with a vapor pressure osmometer (5520;
Wescor, Logan, UT, USA). Urinary levels of sodium and potassium
were measured by flame photometry, and the molybdate method
was used to measure urinary phosphate. A colorimetric assay
(Labtest, Lagoa Santa, Brazil) was used to quantify urinary levels of
glucose, protein, magnesium, and creatinine. Creatinine clearance
(in ml/min/100 g body weight) was determined using the following
formula:
urine creatinineðurine volume ½ml=time ½1440 minÞ
=serum creatinine
Urinary pH was also measured (MP225 pH meter; Mettler Toledo,
Greifensee, Switzerland).
Membrane protein isolation
Kidneys were dissected to separate cortices and medullae. Cortex
and medulla samples were homogenized in ice-cold isolation
solution (200 mmol/l mannitol, 80 mmol/l HEPES, 41 mmol/l
KOH, pH 7.5) containing a protease inhibitor cocktail (Sigma, St
Louis, MO, USA) using a Teflon-pestle glass homogenizer (Schmidt
and Co., Frankfurt am Main, Germany). The homogenates were
centrifuged at low speed (3000 g) for 15 min at 4 1C to remove nuclei
and cell debris. Subsequently, the supernatants were spun at
100,000 g for 1 h at 4 1C (70 Ti rotor, Beckman Coulter, Fullerton,
CA, USA) to produce a pellet containing membrane fractions
enriched with plasma membranes and intracellular vesicles. The
pellets were suspended in isolation solution with protease inhibitors.
Protein concentrations were determined using the Bradford assay
method (Bio-Rad Protein Assay kit; Bio-Rad Laboratories, Hercules,
CA, USA).
Preparation of renal samples for eNOS protein expression
assays
The Teflon-pestle glass homogenizer was used to homogenize kidney
samples in ice-cold isolation solution (200 mM mannitol, 80 mM
HEPES, 41 mM KOH, pH 7.5) containing the protease inhibitor
cocktail. The homogenates were centrifuged at low speed (3000 g)
for 15 min at 4 1C to remove nuclei and cell debris. The pellets were
suspended in isolation solution with protease inhibitors. Protein
concentrations were determined using the Bradford assay method
(Bio-Rad Protein Assay kit; Bio-Rad Laboratories).
Electrophoresis and immunoblotting
Immunoblots of membrane fraction samples were run on poly-
acrylamide minigels: 12.5% gels for AQP2; 10% gels for NaPi-IIa,
NHE3, and the a-ENaC; and 8% gels for NKCC2. After electro-
elution to nitrocellulose membranes (PolyScreen, PVDF Transfer;
Life Science Products, Boston, MA, USA), the blots were blocked
for 1 h with 5% milk and 0.1% Tween-20 in phosphate-buffered
saline (NaCl 8.7 g/l, dibasic phosphate 7.2 mmol/l, and monobasic
phosphate 2.8 mmol/l). The blots were then incubated with one of
the following: anti-AQP2 antibody (1:2000), NHE3 antibody
(1:500), a-ENaC antibody (1:1000); NKCC2 antibody (0.12mg/
ml); or NaPi-IIa antibody (0.54 mg/ml). The labeling was visualized
with horseradish peroxidase-conjugated secondary IgG antibody
(anti-rabbit, 1:2000, Sigma, or anti-goat, 1:5000, Sigma) by using an
enhanced chemiluminescence system (Amersham, Buckingham-
shire, UK). The specific polyclonal antibodies to NKCC2, NHE3 and
NaPi-IIa were kindly supplied by Dr Mark Knepper (NHLBI/NIH,
Bethesda, MD, USA). The specific polyclonal antibodies to AQP2,
a-EnaC, and actin were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
For evaluation of the eNOS isoform, 100mg of total protein
from each sample were separated on an 8% polyacrylamide gel
and transferred to a polyvinylidene difluoride membrane. Immuno-
blotting was performed with eNOS antibody diluted 1:2000 in
Tris-buffered saline and Tween 0.1%. Immunodetection was
accomplished using the appropriate anti-mouse horseradish peroxi-
dase-conjugated secondary antibody (1:2000 in Tris-buffered saline
and 0.1% Tween) and the enhanced chemiluminescence system.
To control for loading, the blots were incubated with actin
antibody (1:3000, Santa Cruz Biotechnology). The labeling was
visualized with horseradish peroxidase-conjugated secondary IgG
antibody (anti-goat, diluted 1:5000; Sigma).
Quantification of kidney levels of proteins
The enhanced chemiluminescence films presenting bands within the
linear range were scanned using a video imager (ImageMaster VDS;
Pharmacia Biotech, Uppsala, Sweden). All densitometry values were
normalized to those obtained for actin protein abundance.
Statistical analysis
All quantitative data are expressed as mean±s.e.m. Differences among
the means of multiple parameters were analyzed by one-way analysis
of variance followed by the Student–Newman–Keuls test or Tukey’s
test. Values of Po0.05 were considered as statistically significant.
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